Pregnancy: Discontinue semaglutide or tirzepatide at least 2 months before a planned pregnancy
doi:10.1056/NEJMoa2032183 Jastreboff AM, Aronne LJ, Ahmad NN, et al
Fatigue affects roughly 8-12% of Retatrutide users, typically peaking during weeks 4 through 10 of treatment
Participation in the BALANCE Model is voluntary for drug manufacturers, state Medicaid programs, and Medicare Part D plans, but there was insufficient interest among Medicare Part D plans to move forward in 2027 Participation in BALANCE is voluntary for drug manufacturers, state Medicaid agencies, and Medicare Part D plans
Post-hoc analysis of the SURMOUNT trial data found that tirzepatide relative to placebo was not associated with increased risk of depressive symptoms
Its also not recommended for people with heart disease, high blood pressure, or a history of substance abuse